Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tac/MTX/Rux vs PTCy/Tac/MMF in Allogeneic Stem Cell Transplantation
NCT06615050Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Apr 2025
- Primary completion
- Jan 2031
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by Incyte. Started Apr 2025; status: recruiting.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06615050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06615050.